BACKGROUND: Skeletal muscle alterations are associated with higher mortality and morbidity in patients with liver cirrhosis. Assessing these changes seems to be a promising method for identifying patients at a high risk of poor outcomes following liver transplantation (LT). This is particularly important given the current global shortage of organ donors. However, evidence of the impact of these alterations on the prognosis of patients undergoing LT is inconclusive. The aim of our prospective study was to evaluate the impact of skeletal muscle changes, reflected in sarcopenia, myosteatosis and metabolic changes in the calf muscles, on perioperative outcomes and long-term survival after LT. We also sought to determine the posttransplant evolution of the resting muscle metabolism. METHODS: We examined 134 adult LT candidates. Of these, 105 underwent LT. Sarcopenia and myosteatosis were diagnosed by measuring the skeletal muscle index and mean psoas muscle radiation attenuation, respectively, which were obtained from computed tomography (CT) scans taken during pretransplant assessment. Additionally, patients underwent 31P MR spectroscopy (MRS) of the calf muscles at rest before LT and 6, 12 and 24 months thereafter. The median follow-up was 6 years. RESULTS: Patients with abnormal 31P MRS results and CT-diagnosed myosteatosis prior to LT had significantly worse long-term survival after LT (hazard ratio (HR), 3.36; 95% confidence interval (CI), 1.48-7.60; p = 0.0021 and HR, 2.58; 95% CI, 1.06-6.29; p = 0.03, respectively). Multivariable analysis showed that abnormal 31P MR spectra (HR, 3.40; 95% CI, 1.50-7.71; p = 0.003) were a better predictor of worse long-term survival after LT than myosteatosis (HR, 2.78; 95% CI, 1.14-6.78; p = 0.025). Patients with abnormal 31P MR spectra had higher blood loss during LT (p = 0.038), required a higher number of red blood cell transfusions (p = 0.006) and stayed longer in ICU (p = 0.041) and hospital (p = 0.007). Myosteatosis was associated with more revision surgeries following LT (p = 0.038) and a higher number of received red blood cell transfusion units (p = 0.002). Sarcopenia had no significant effect on posttransplant patient survival. An improvement in the resting metabolism of the calf muscles was observed at 12 and 24 months after LT. CONCLUSIONS: Abnormal 31P MRS results of calf muscles were superior to CT-based diagnosis of myosteatosis and sarcopenia in predicting perioperative complications and long-term survival after LT. Resting muscle metabolism normalized 1 year after LT in most recipients.

1st Faculty of Medicine Charles University Prague Czech Republic

Department of Anatomy 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Data Science Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Diagnostic and Interventional Radiology Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Hepatogastroenterology Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Transplantation Surgery Institute for Clinical and Experimental Medicine Prague Czech Republic

Institute of Physiology 1st Faculty of Medicine Charles University Prague Czech Republic

See more in PubMed

Nachit M. and Leclercq I. A., “Emerging Awareness on the Importance of Skeletal Muscle in Liver Diseases: Time to Dig Deeper Into Mechanisms!,” Clinical Science (London, England) 133, no. 3 (2019): 465–481. PubMed

Tandon P., Montano‐Loza A. J., Lai J. C., Dasarathy S., and Merli M., “Sarcopenia and Frailty in Decompensated Cirrhosis,” Journal of Hepatology 75, no. Suppl 1 (2021): S147–S162. PubMed PMC

Carey E. J., Lai J. C., Sonnenday C., et al., “A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation,” Hepatology 70, no. 5 (2019): 1816–1829. PubMed PMC

Tantai X., Liu Y., Yeo Y. H., et al., “Effect of Sarcopenia on Survival in Patients With Cirrhosis: A Meta‐Analysis,” Journal of Hepatology 76, no. 3 (2022): 588–599. PubMed

Merli M., Berzigotti A., Zelber‐Sagi S., et al., “EASL Clinical Practice Guidelines on Nutrition in Chronic Liver Disease,” Journal of Hepatology 70, no. 1 (2019): 172–193. PubMed PMC

Bhanji R. A., Moctezuma‐Velazquez C., Duarte‐Rojo A., et al., “Myosteatosis and Sarcopenia Are Associated With Hepatic Encephalopathy in Patients With Cirrhosis,” Hepatology International 12, no. 4 (2018): 377–386. PubMed

Czigany Z., Kramp W., Bednarsch J., et al., “Myosteatosis to Predict Inferior Perioperative Outcome in Patients Undergoing Orthotopic Liver Transplantation,” American Journal of Transplantation 20, no. 2 (2020): 493–503. PubMed

Meister F. A., Bednarsch J., Amygdalos I., et al., “Various Myosteatosis Selection Criteria and Their Value in the Assessment of Short‐ and Long‐Term Outcomes Following Liver Transplantation,” Scientific Reports 11, no. 1 (2021): 13368. PubMed PMC

Czigany Z., Kramp W., Lurje I., et al., “The Role of Recipient Myosteatosis in Graft and Patient Survival After Deceased Donor Liver Transplantation,” Journal of Cachexia, Sarcopenia and Muscle 12, no. 2 (2021): 358–367. PubMed PMC

Bhanji R. A., Narayanan P., Moynagh M. R., et al., “Differing Impact of Sarcopenia and Frailty in Nonalcoholic Steatohepatitis and Alcoholic Liver Disease,” Liver Transplantation 25, no. 1 (2019): 14–24. PubMed PMC

Meyerspeer M., Boesch C., Cameron D., et al., “31P Magnetic Resonance Spectroscopy in Skeletal Muscle: Experts' Consensus Recommendations,” NMR in Biomedicine 34, no. 5 (2020): e4246. PubMed PMC

Taylor D. J., Kemp G. J., and Radda G. K., “Bioenergetics of Skeletal Muscle in Mitochondrial Myopathy,” Journal of the Neurological Sciences 127, no. 2 (1994): 198–206. PubMed

Lodi R., Taylor D. J., Tabrizi S. J., et al., “In Vivo Skeletal Muscle Mitochondrial Function in Leber's Hereditary Optic Neuropathy Assessed by 31P Magnetic Resonance Spectroscopy,” Annals of Neurology 42, no. 4 (1997): 573–579. PubMed

Sleigh A., Stears A., Thackray K., et al., “Mitochondrial Oxidative Phosphorylation Is Impaired in Patients With Congenital Lipodystrophy,” The Journal of Clinical Endocrinology and Metabolism 97, no. 3 (2012): E438–E442. PubMed PMC

Park J. H., Phothimat P., Oates C. T., Hernanz‐Schulman M., and Olsen N. J., “Use of P‐31 Magnetic Resonance Spectroscopy to Detect Metabolic Abnormalities in Muscles of Patients With Fibromyalgia,” Arthritis and Rheumatism 41, no. 3 (1998): 406–413. PubMed

Carey E. J., Lai J. C., Wang C. W., et al., “A Multi‐Center Study to Define Sarcopenia in Patients With End‐Stage Liver Disease,” Liver Transplantation 23, no. 5 (2017): 625–633. PubMed PMC

Naressi A., Couturier C., Devos J. M., et al., “Java‐Based Graphical User Interface for the MRUI Quantitation Package,” Magma 12, no. 2–3 (2001): 141–152. PubMed

Stefan D., Di C. F., Andrasescu A., et al., “Quantitation of Magnetic Resonance Spectroscopy Signals: The jMRUI Software Package,” Measurement Science and Technology 20, no. 10 (2009): 104035.

Moon R. B. and Richards J. H., “Determination of Intracellular pH by 31P Magnetic Resonance,” The Journal of Biological Chemistry 248, no. 20 (1973): 7276–7278. PubMed

Schneider C. A., Rasband W. S., and Eliceiri K. W., “NIH Image to ImageJ: 25 Years of Image Analysis,” Nature Methods 9, no. 7 (2012): 671–675. PubMed PMC

Sedivy P., Drobny M., Dezortova M., et al., “31P‐MR Spectroscopy in Patients With Mild and Serious Lower Limb Ischemia,” International Angiology 37, no. 4 (2018): 293–299. PubMed

Reichelt S., Pratschke J., Engelmann C., Neumann U. P., Lurje G., and Czigany Z., “Body Composition and the Skeletal Muscle Compartment in Liver Transplantation: Turning Challenges Into Opportunities,” American Journal of Transplantation 22, no. 8 (2022): 1943–1957. PubMed

Cruz‐Jentoft A. J., Bahat G., Bauer J., et al., “Sarcopenia: Revised European Consensus on Definition and Diagnosis,” Age and Ageing 48, no. 4 (2019): 601. PubMed PMC

van Vugt J. L. A., Levolger S., de Bruin R. W. F., van Rosmalen J., Metselaar H. J., and IJzermans J. N. M., “Systematic Review and Meta‐Analysis of the Impact of Computed Tomography–Assessed Skeletal Muscle Mass on Outcome in Patients Awaiting or Undergoing Liver Transplantation,” American Journal of Transplantation 16, no. 8 (2016): 2277–2292. PubMed

Irwin N. E. A., Fabian J., Hari K. R., Lorentz L., Mahomed A., and Botha J. F., “Myosteatosis, the More Significant Predictor of Outcome: An Analysis of the Impact of Myosteatosis, Sarcopenia, and Sarcopenic Obesity on Liver Transplant Outcomes in Johannesburg, South Africa,” Experimental and Clinical Transplantation 19, no. 9 (2021): 948–955. PubMed

Kemp G. J., Meyerspeer M., and Moser E., “Absolute Quantification of Phosphorus Metabolite Concentrations in Human Muscle in Vivo by 31P MRS: A Quantitative Review,” NMR in Biomedicine 20, no. 6 (2007): 555–565. PubMed

Åberg F., Nordin A., Mäkisalo H., and Isoniemi H., “Who Is Too Healthy and Who Is Too Sick for Liver Transplantation: External Validation of Prognostic Scores and Survival‐Benefit Estimation,” Scandinavian Journal of Gastroenterology 50, no. 9 (2015): 1144–1151. PubMed

Schrem H., Focken M., Gunson B., et al., “The New Liver Allocation Score for Transplantation Is Validated and Improved Transplant Survival Benefit in Germany but Not in the United Kingdom,” Liver Transplantation 22, no. 6 (2016): 743–756. PubMed